Alendronate-hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells

Biomaterials

Volumn 29, Issue 7, 2008, Pages 790-796

  Boanini, Elisa ^a   Torricelli, Paola ^b   Gazzano, Massimo ^c   Giardino, Roberto ^a,b   Bigi, Adriana ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c CNR   (Italy)

Author keywords

Bisphosphonate; Hydroxyapatite; Osteoblast; Osteoclast

Indexed keywords

CELL CULTURE; ENZYME ACTIVITY; HYDROXYAPATITE; NANOCOMPOSITES; NANOCRYSTALS; PATHOLOGY;

BISPHOSPHONATES; BONE LOSS; CELLS RESPONSE; OSTEOCLASTS;

OSTEOBLASTS;

ALENDRONIC ACID; HYDROXYAPATITE; NANOCOMPOSITE; NANOCRYSTAL;

ARTICLE; BONE CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL INTERACTION; CELL PROLIFERATION; CELL STRUCTURE; COLLAGEN DEGRADATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; MINERALIZATION; MOLECULAR INTERACTION; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

ALENDRONATE; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; DURAPATITE; HUMANS; MATRIX METALLOPROTEINASES; MICROSCOPY, ELECTRON, SCANNING; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NANOCOMPOSITES; OSTEOBLASTS; X-RAY DIFFRACTION;

EID: 37249013797     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2007.10.040     Document Type: Article

References (27)

1. Fleisch H. Bisphosphonates in bone disease, from the laboratory to the patient (2000), Academic Press, San Diego
2. Chesnut III C., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 (2004) 1241-1249
3. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al. Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344 (2001) 333-340
4. Coxon F.P., Thompson K., and Rogers M.J. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharm 6 (2006) 307-312
5. Leu C.T., Luegmayr E., Freedman L.P., Rodan G.A., and Reszka A.A. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 38 (2006) 628-636
6. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38 (2006) 617-627
7. Papapoulos S.E. Bisphosphonate actions: physical chemistry revisited. Bone 38 (2006) 613-616
8. Russell R.G.G. Determinants of structure-function relationships among bisphosphonates. Bone 40 (2007) S21-S25
9. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 19 (1998) 80-100
10. Ott S.M. Fractures after long-term alendronate therapy [Letter]. J Clin Endocrinol Metab 86 (2001) 1835-1836
11. Ott S.M. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 90 (2005) 1897-1899
12. Boanini E., Gazzano M., Rubini K., and Bigi A. Composite nanocrystals provide new insight on alendronate interaction with hydroxyapatite structure. Adv Mater 19 (2007) 2499-2502
13. Brückner S. Profile analysis of X-ray diffraction data from powder polymer samples. Chim Ind 70 (1988) 48-53
14. Kuljanin J., Janković I., Nedeljković J., Prstojević D., and Marinković V. Spectrophotometric determination of alendronate in pharmaceutical formulations via complex formation with Fe(III) ions. J Pharm Biomed Anal 28 (2002) 1215-1220
15. Russell R.G., Croucher P.I., and Rogers M.J. Bisphosphonates: pharmacology, mechanism of action and clinical uses. Osteoporos Int 9S (1999) 66S-80S
16. Flanagan A.M., and Chambers T.J. Inhibition of bone resorption by bisphosphonates, osteoclasts, and bone. Calcify Tissue Int 49 (1991) 407-415
17. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Monkkonen J., et al. Cellular and molecular mechanisms of action of biphosphonates. Cancer 88 (2000) 2961-2978
18. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88 (1991) 2095-2105
19. Malaval L., Liu F., Roche P., and Aubin J.E. Kinetics of osteoprogenitor proliferation and osteoblast differentiation in vitro. J Cell Biochem 74 (1999) 616-627
20. Atsushi E., Korenori O., Satoshi I., Shigeyuki E., Takayoshi N., and Yukichi U. Effects of α-TCP and TetCP on MC3T3-E1 proliferation, differentiation and mineralization. Biomaterials 24 (2003) 831-836
21. Franceschi R.T., and Iyer B.S. Relationship between collagen synthesis and expression of the osteoblast phenotype in MC3T3-E1 cells. J Bone Miner Res 7 (1992) 235-246
22. Cowles E.A., DeRome D., Pastizzo G., Brailey L.L., and Gronowicz G.A. Mineralization and the expression of matrix proteins during in vivo bone development. Calcif Tissue Int 62 (1998) 74-82
23. Fini M., Giardino R., Borsari V., Torricelli P., Rimondini L., Giavaresi G., et al. In vitro behaviour of osteoblasts cultured on orthopaedic biomaterials with different surface roughness, uncoated and fluorohydroxyapatite-coated, relative to the in vivo osteointegration rate. Int J Artif Organs 26 (2003) 520-528
24. Mayr-Wohlfart U., Fiedler J Gunther K.P., Puhl W., and Kessler S. Proliferation and differentiation rates of a human osteoblast-like cell line (SaOS-2) in contact with different bone substitute materials. J Biomed Mater Res 57 (2001) 132-139
25. Kim Y.H., Kim G.S., and Baek J.H. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp Mol Med 34 2 (2002) 145-151
26. Dobnig H., Hofbauer L.C., Viereck V., Obermayer-Pietsch B., and Fahrleitner-Pammer A. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int 17 5 (2006) 693-703
27. Teronen O., Heikkila P., Konttinen Y.T., Laitinen M., Salo T., Hanemaaijer R., et al. MMP inhibition and downregulation by bisphosphonates. Ann NY Acad Sci 878 (1999) 453-465